Letter to the Editor
Lack of strong effect modification by NFE2L2/CYP3A5/ABO of the risk of venous thrombosis associated with oral hormone therapy
- Disclaimers: part of this work was presented as a poster at the 5th International Symposium on Women's Health Issues in Thrombosis and Haemostasis (Vienna, February 2013).
- Manuscript handled by: F. R. Rosendaal
- Final decision: F. R. Rosendaal, 23 May 2013
Correspondence: Marc Blondon, University of Washington, Cardiovascular Health Research Unit, Metropolitan Park East Tower, 1730 Minor Ave, Suite 1360, Seattle, WA 98101, USA.
Tel.: +1 206 287 2777; fax: +1 206 287 2662.
E-mail: email@example.com, firstname.lastname@example.org